CHELSEA, Mass.--(BUSINESS WIRE)--Civitas Therapeutics, Inc., a biopharmaceutical company with a lead program in Parkinson’s disease that leverages the ARCUS ® respiratory delivery platform, today ...
Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 SPAN-PD trial met primary endpoint: CVT-301 showed statistically significant improvement of motor function compared to placebo New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback